Compass Therapeutics
Home
About
Platform
Pipeline
Join Us
News
Investors
Contact
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity
Post navigation
Previous Post
Previous
CTX-8371, a Novel Bispecific Targeting both PD-1 and PD-L1, is more Potent than Combination anti-PD-1 and PD-L1 Therapy and Provides Enhanced Protection from Tumors in vivo
Home
About
Platform
Pipeline
Join Us
News
Contact
Investors